Denomme William J, Simard Isabelle, Shane Matthew S
The Clinical Affective Neuroscience Laboratory for Discovery and Innovation, Faculty of Social Science and Humanities, University of Ontario Institute of Technology, Oshawa, ON, Canada.
The Mind Research Network, The University of New Mexico, Albuquerque, NM, United States.
Front Hum Neurosci. 2018 Sep 4;12:350. doi: 10.3389/fnhum.2018.00350. eCollection 2018.
Previous studies suggest that psychopathic traits commonly present as comorbid with substance use disorders. Moreover, neuroimaging and psychometric findings suggest that psychopathic traits may predispose individuals to a sensitized reward response to drugs. Given that substance use disorders are characterized by a neurocognitive bias toward drug-reward relative to non-drug reward, it is possible that heightened psychopathic characteristics may further predispose to this processing bias. To evaluate this possibility, we assessed psychopathic traits (measured using the PCL-R; Hare, 2003) in 105 probationers/parolees and evaluated the relationship between PCL-R scores, lifetime duration of drug use, and biases in neural response to drug- compared to food-related videos. Psychopathic traits (potentially driven by interpersonal/affective traits) were positively correlated with drug > food reactivity within the right insula and left amygdala. In addition, psychopathic traits modulated the relationship between drug use and drug > food reactivity within the left dorsomedial prefrontal cortex, right insula, and left caudate nucleus. Specifically, lifetime duration of drug use correlated positively with drug > food reactivity in participants with lower levels of psychopathic traits and correlated negatively with drug > food reactivity in individuals with higher levels of psychopathic traits. These results help reconcile prior studies on psychopathy and drug-stimulus processing and provide neurocognitive support for the notion that psychopathic traits serve as an underlying risk factor for substance use disorders. These results suggest that different treatment regimens for substance abuse for individuals with higher or lower levels of psychopathy may be beneficial and suggest that reduction of neurocognitive biases to drug-related stimuli may offer useful targets for future treatment protocols.
先前的研究表明,精神病态特质通常与物质使用障碍并发。此外,神经影像学和心理测量结果表明,精神病态特质可能使个体对药物产生敏感的奖赏反应。鉴于物质使用障碍的特征是相对于非药物奖赏而言,对药物奖赏存在神经认知偏差,因此有可能更高的精神病态特征可能进一步使个体易出现这种加工偏差。为了评估这种可能性,我们对105名缓刑犯/假释人员的精神病态特质进行了评估(使用PCL-R量表测量;Hare,2003),并评估了PCL-R得分、终生药物使用时长以及与食物相关视频相比对药物相关视频的神经反应偏差之间的关系。精神病态特质(可能由人际/情感特质驱动)与右侧脑岛和左侧杏仁核内药物>食物的反应性呈正相关。此外,精神病态特质调节了左侧背内侧前额叶皮质、右侧脑岛和左侧尾状核内药物使用与药物>食物反应性之间的关系。具体而言,终生药物使用时长在精神病态特质水平较低的参与者中与药物>食物反应性呈正相关,而在精神病态特质水平较高的个体中与药物>食物反应性呈负相关。这些结果有助于调和先前关于精神病态与药物刺激加工的研究,并为精神病态特质是物质使用障碍潜在危险因素这一观点提供神经认知支持。这些结果表明,针对精神病态水平较高或较低个体的不同药物滥用治疗方案可能是有益的,并表明减少对药物相关刺激的神经认知偏差可能为未来的治疗方案提供有用的靶点。